Abstract
Neurofibromatosis type 1 (NF1) is one of the most common neurocutaneous disorders. Some NF1 patients develop benign large plexiform neurofibroma(s) at birth, which can then transform into a malignant peripheral nerve sheath tumor (MPNST). There is no curative treatment for this rapidly progressive and easily metastatic neurofibrosarcoma. Photodynamic therapy (PDT) has been developed as an anti-cancer treatment, and 5-aminolevulinic (ALA) mediated PDT (ALA-PDT) has been used to treat cutaneous skin and oral neoplasms. Doxycycline, a tetracycline derivative, can substantially reduce the tumor burden in human and animal models, in addition to its antimicrobial effects. The purpose of this study was to evaluate the effect and to investigate the mechanism of action of combined doxycycline and ALA-PDT treatment of MPNST cells. An 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed that the combination of ALA-PDT and doxycycline significantly reduce MPNST survival rate, compared to cells treated with each therapy alone. Isobologram analysis showed that the combined treatment had a synergistic effect. The increased cytotoxic activity could be seen by an increase in cellular protoporphyrin IX (PpIX) accumulation. Furthermore, we found that the higher retention of PpIX was mainly due to increasing ALA uptake, rather than activity changes of the enzymes porphobilinogen deaminase and ferrochelatase. The combined treatment inhibited tumor growth in different tumor cell lines, but not in normal human Schwann cells or fibroblasts. Similarly, a synergistic interaction was also found in cells treated with ALA-PDT combined with minocycline, but not tetracycline. In summary, doxycycline can potentiate the effect of ALA-PDT to kill tumor cells. This increased potency allows for a dose reduction of doxycycline and photodynamic radiation, reducing the occurrence of toxic side effects in vivo.
Highlights
Photodynamic therapy (PDT), a new approach to cancer treatment, uses photosensitizers (PS) and light to generate reactive oxygen species, which can interact with biomolecules and subcellular organelles to interrupt key molecular functions
To elucidate the mechanism involved in the increased cytotoxicity caused by the combined aminolevulinic acid (ALA)-PDT/doxycycline treatment, we examined whether the combined treatment caused an increase in protoporphyrin IX (PpIX) levels in the cells
We demonstrated that doxycycline and its derivative could selectively enhance the therapeutic efficacy of ALA-mediated PDT in a malignant peripheral nerve sheath tumor (MPNST) derived cell line, S462
Summary
Photodynamic therapy (PDT), a new approach to cancer treatment, uses photosensitizers (PS) and light to generate reactive oxygen species, which can interact with biomolecules and subcellular organelles to interrupt key molecular functions. This photoreaction leads to cell death and destruction of tissues [1]. 5-aminolevulinic acid (ALA) itself is not a photosensitizer; but exogenously applied ALA leads to the increased formation of protoporphyrin IX (PpIX, a photosensitizer) by a series of enzymes in the heme biosynthetic pathway [2]. The other is the formation of heme via the addition of a ferrous iron to PpIX, which is controlled by the rate-limiting enzyme, ferrochelatase (FC). Cancer cells usually have high rate of glycolysis followed by lactic acid fermentation (Warburg effect), resulting in abnormalities of iron metabolism and errors in iron insertion which lead to the enhanced accumulation of PpIX in cancer cells [5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.